Lee Ainslie's RCKT Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 3.57 M shares of Rocket Pharmaceuticals, Inc. (RCKT) worth $12.77 M, representing 0.15% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Lee Ainslie has maintained a strategic position in RCKT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 3.16 M shares. Largest reduction occurred in Q4 2025, reducing 5.96 M shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Rocket Pharmaceuticals (RCKT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Rocket Pharmaceuticals (RCKT) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.05 M | Add 41.95% | 3.57 M | $3.58 |
| Q4 2025 | -5.96 M | Reduce 70.32% | 2.51 M | $3.51 |
| Q3 2025 | +104,531 | Add 1.25% | 8.47 M | $3.26 |
| Q2 2025 | +3.16 M | Add 60.87% | 8.36 M | $2.45 |
| Q1 2025 | +318 | Add 0.01% | 5.2 M | $6.67 |
| Q4 2024 | +1.08 M | Add 26.23% | 5.2 M | $12.57 |
| Q3 2024 | +190,360 | Add 4.85% | 4.12 M | $18.47 |
| Q2 2024 | +40,000 | Add 1.03% | 3.93 M | $21.53 |
| Q1 2024 | -145,756 | Reduce 3.61% | 3.89 M | $26.94 |
| Q4 2023 | -1.6 M | Reduce 28.35% | 4.03 M | $29.97 |
| Q3 2023 | +1.25 M | Add 28.54% | 5.63 M | $20.49 |
| Q2 2023 | -27,653 | Reduce 0.63% | 4.38 M | $19.87 |
| Q1 2023 | +1.01 M | Add 29.80% | 4.41 M | $17.13 |
| Q4 2022 | +863,452 | Add 34.10% | 3.4 M | $19.57 |
| Q2 2022 | +399,200 | Add 18.71% | 2.53 M | $13.76 |
| Q1 2022 | +238,200 | Add 12.57% | 2.13 M | $15.86 |
| Q4 2021 | +234,850 | Add 14.15% | 1.89 M | $21.83 |
| Q3 2021 | +1.49 M | Add 854.71% | 1.66 M | $29.89 |
| Q2 2021 | +173,887 | New Buy | 173,887 | $44.29 |
Lee Ainslie's Rocket Pharmaceuticals Investment FAQs
Lee Ainslie first purchased Rocket Pharmaceuticals, Inc. (RCKT) in Q2 2021, acquiring 173,887 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Rocket Pharmaceuticals, Inc. (RCKT) for 20 quarters since Q2 2021.
Lee Ainslie's largest addition to Rocket Pharmaceuticals, Inc. (RCKT) was in Q2 2025, adding 8,363,813 shares worth $20.49 M.
According to the latest 13F filing for Q1 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 3,567,372 shares of Rocket Pharmaceuticals, Inc. (RCKT), valued at approximately $12.77 M.
As of the Q1 2026 filing, Rocket Pharmaceuticals, Inc. (RCKT) represents approximately 0.15% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Rocket Pharmaceuticals, Inc. (RCKT) was 8,468,344 shares, as reported at the end of Q3 2025.